Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390523 | 1.00 | DRD2 (0.49) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL25039653 | 0.88 | DRD2 (0.49) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL31206080 | 0.88 | DRD2 (0.49) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL25039624 | 0.88 | DRD2 (0.49) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL1849161 | 0.88 | DRD2 (0.56) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL1849163 | 0.88 | DRD2 (0.56) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL31206158 | 0.87 | DRD2 (0.47) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL2392409 | 0.85 | DRD2 (0.45) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL2392411 | 0.85 | DRD2 (0.45) | DRD2DRD3KDM1AMAOBCRHR1 | |
| SCHEMBL31008908 | 0.84 | DRD2 (0.46) | DRD2DRD3KDM1AMAOBCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-11932624-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-9073898-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-8969351-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| EP-2640467-B1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2516009-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | DRD2 4088/4885DRD3 4236/4885KDM1A 822/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | DRD2 3978/4885DRD3 4257/4885KDM1A 304/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | DRD2 3318/4885DRD3 3527/4885KDM1A 397/4885 |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | DRD2 1974/4885DRD3 2076/4885KDM1A 1216/4885 |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | MDM4, TP53, TP53BP1 | DRD2 4207/4885DRD3 4442/4885KDM1A 2248/4885 |
| US-11932624-B2 | MDM2 degraders and uses thereof | MDM2, TP53, MDM4 | DRD2 4088/4885DRD3 4236/4885KDM1A 822/4885 |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | MDM4, MDM2, TP53 | DRD2 1974/4885DRD3 2076/4885KDM1A 1216/4885 |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | MDM4, TP53, TP53BP1 | DRD2 4240/4885DRD3 4455/4885KDM1A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.